Arvinas, Inc. (NASDAQ:ARVN) is New Leaf Venture Partners L.L.C.’s Largest Position

New Leaf Venture Partners L.L.C. decreased its holdings in shares of Arvinas, Inc. (NASDAQ:ARVNGet Rating) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,289,521 shares of the company’s stock after selling 18,666 shares during the quarter. Arvinas accounts for approximately 38.4% of New Leaf Venture Partners L.L.C.’s portfolio, making the stock its largest position. New Leaf Venture Partners L.L.C. owned about 2.44% of Arvinas worth $105,921,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ARVN. Morgan Stanley boosted its stake in Arvinas by 208.5% in the second quarter. Morgan Stanley now owns 753,343 shares of the company’s stock worth $58,008,000 after buying an additional 509,173 shares in the last quarter. Invesco Ltd. boosted its stake in Arvinas by 238.8% in the third quarter. Invesco Ltd. now owns 482,710 shares of the company’s stock worth $39,669,000 after buying an additional 340,242 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its stake in Arvinas by 51.1% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 522,306 shares of the company’s stock worth $42,902,000 after buying an additional 176,712 shares in the last quarter. BlackRock Inc. boosted its stake in Arvinas by 5.3% in the third quarter. BlackRock Inc. now owns 3,275,456 shares of the company’s stock worth $269,178,000 after buying an additional 165,086 shares in the last quarter. Finally, Frazier Management LLC purchased a new stake in Arvinas in the fourth quarter worth approximately $13,451,000. 84.52% of the stock is owned by institutional investors.

Shares of Arvinas stock traded up $2.88 during midday trading on Tuesday, reaching $45.33. 463,325 shares of the company’s stock traded hands, compared to its average volume of 488,647. The stock has a 50 day moving average of $61.34 and a 200-day moving average of $69.98. The company has a market cap of $2.41 billion, a PE ratio of -10.87 and a beta of 2.05. Arvinas, Inc. has a 12 month low of $37.41 and a 12 month high of $108.46.

Arvinas (NASDAQ:ARVNGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.29). The firm had revenue of $24.20 million during the quarter, compared to the consensus estimate of $25.51 million. Arvinas had a negative return on equity of 29.38% and a negative net margin of 326.72%. The company’s revenue for the quarter was up 340.0% compared to the same quarter last year. Research analysts anticipate that Arvinas, Inc. will post -4.52 EPS for the current year.

In other news, Director Briggs Morrison sold 20,960 shares of the stock in a transaction on Thursday, April 14th. The stock was sold at an average price of $66.44, for a total value of $1,392,582.40. Following the sale, the director now directly owns 19,976 shares of the company’s stock, valued at $1,327,205.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Sean A. Cassidy sold 15,000 shares of the stock in a transaction on Friday, March 11th. The stock was sold at an average price of $70.00, for a total value of $1,050,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,446 shares of company stock worth $2,985,177. Insiders own 6.45% of the company’s stock.

ARVN has been the subject of several research reports. The Goldman Sachs Group cut their target price on Arvinas from $157.00 to $110.00 and set a “buy” rating for the company in a research note on Tuesday, March 1st. Wells Fargo & Company assumed coverage on Arvinas in a research report on Thursday, February 10th. They issued an “overweight” rating and a $98.00 price objective for the company. SVB Leerink lowered their price objective on Arvinas from $97.00 to $91.00 and set an “outperform” rating for the company in a research report on Friday, February 18th. Stifel Europe lowered their price objective on Arvinas from $85.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday, May 5th. Finally, Credit Suisse Group assumed coverage on Arvinas in a research report on Thursday, April 28th. They issued an “outperform” rating and a $104.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $107.33.

Arvinas Profile (Get Rating)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

Read More

Institutional Ownership by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.